印明柱

印明柱，博士，現為重慶大學附屬三峽醫院特聘教授、博士生導師。

基本介紹

  • 中文名：印明柱
  • 學位/學歷：博士
  • 職業：教師
人物經歷,教育經歷,工作經歷,研究領域,承擔項目,個人著作,發明專利,發表文章,

人物經歷

教育經歷

2018年，耶魯大學&中國藥科大學聯合培養 中西醫結合專業（博士）；
2011年，哈爾濱醫科大學 腫瘤學專業（碩士）；
2008年，哈爾濱醫科大學 臨床醫學專業（本科）；

工作經歷

2023- 重慶大學附屬三峽醫院特聘教授，博士生導師，腫瘤早期診斷中心、臨床病理中心及臨床研究中心主任；擬任重慶大學轉化醫學中心主任；
2020- 美國耶魯大學醫學院，病理科，兼職助理教授；
2018-2022，中南大學湘雅醫院，皮膚科副主任、皮膚健康與疾病湖南省工程研究中心常務副主任，特聘教授；博士生導師；
2017-2018年，美國耶魯大學醫學院，病理科，副研究員；
2013-2016年，美國耶魯大學醫學院，病理科，博士後；
2012年，美國國立衛生研究院抗衰老研究所（NIH/NIA）遺傳系博士後；
2011年，哈爾濱醫科大學附屬腫瘤醫院，主治醫師。

研究領域

主要從事於腫瘤表觀遺傳學、癌症生物學、腫瘤免疫學及創新藥物轉化等方面的研究。最早系統闡述了腫瘤相關巨噬細胞主導腫瘤轉移的作用機理，闡明KDM5B、CECR2和BET等表觀遺傳新靶點在腫瘤生長、轉移中的功能及其腫瘤免疫調節機制；同時針對表觀遺傳新靶點BET開發了新一代小分子抑制劑NHWD-870，該項目現已完成臨床Ⅰ期試驗；另外，首次報導了表觀遺傳新靶點CECR2通過調控腫瘤微環境調節腫瘤轉移新機制，為該靶點後期臨床套用提供理論依據。

承擔項目

2019年1月至2022年12月，主持國家自然科學基金面上項目——基於BRD4通過c-MYC-MYH9軸調控MYH9與HIF-1α相互作用探討BET抑制劑防治黑素瘤轉移的機制研究。
2021年1月至2023年12月，主持湖南省傑出青年基金項目——皮膚疾病藥理學。
2021年1月至2024年12月，主持國家自然科學基金面上項目——BRD4及其抑制劑調控HIPPO/YAP1通路防治黑素瘤增殖、侵襲及轉移機制研究。
2022年12月至2025年12月，主持國家重點研發計畫子課題——老年常見皮膚病精準分型和診斷研究。

個人著作

論文、著作名稱
年份
排名
發表刊物名稱
本人作用和主要貢獻
教輔《輕鬆學習病理學》
2018
主編
湖北科學技術出版社 （ISBN：978-7-5352-9643-6）
負責本書整體的設計、排版、校對等工作，同時負責第7章節的撰寫工作
教輔《臨床病理生理學》
2022
主編
湖北科學技術出版社 （ISBN：978-7-5706-2212-2）
負責本書整體的設計、排版、校對等工作，同時負責10，18和20章節的撰寫工作
專著《腫瘤標誌物》
2022
編委
人民衛生出版社
（ISBN：9787117330817）
負責第3章-單細胞技術進展內容的編寫工作
教材《臨床研究倫理學》
未出版
編委
人民衛生出版社（書號：未出）
負責第5章-臨床研究中人類遺傳資源管理內容的編寫工作
譯著《ABC皮膚病》
2023
主譯
湖南科學技術出版社（ISBN：978-7-5710-1869-6）
負責本書整體的設計、排版、校對及部分翻譯工作

發明專利

1. 專利名稱：宮頸癌患者使用紫杉醇和順鉑進行化療敏感性預測方法。發明人：侯艷，印明柱，孫風宇，婁閣，李康。申請號：201510164414.2
2. 專利名稱：雜環化合物及其鹽、製備方法、用途和藥物。發明人：印明柱，陳翔。專利號：ZL2018 1 1204859.9 授權號：CN109134448 B
3. 專利名稱：螢光酶抑制劑篩選模型建立方法及螢光酶抑制劑篩選方法。發明人：印明柱、曹東升、楊梓宜、陳翔。申請號：202010715628.5
4. 專利名稱：分子靶標蛋白的篩選方法、裝置、計算機設備和存儲介質。發明人：印明柱、曹東升、楊素青、陳翔。申請號：202010716290.5
5. 專利名稱：膠體篩選模型的構建方法和膠體篩選方法。發明人：曹東升、印明柱、陳翔、楊梓宜。申請號：202010818121.2
6. 專利名稱：藥物與靶點間的相互作用關係預測方法及裝置。發明人：曹東升、印明柱、陳翔、楊素青、程岩。申請號：202010824226.9
7. 專利名稱：誘導肝毒性預測方法、裝置、計算機設備及存儲介質。發明人：曹東升、印明柱、陳翔、付麗、劉璐。申請號：202010835987.4
8. 專利名稱：藥物副作用關係預測方法、系統、計算機設備和存儲介質。發明人：曹東升、印明柱、陳翔、楊素青。申請號：202010837504.4
9. 專利名稱：細胞分類方法、裝置、計算機設備和存儲介質。發明人：印明柱、李軼群、陳翔。申請號：202010840988.8
10. 專利名稱：原代肢端黑色素瘤細胞的培養方法及培養試劑盒。發明人：印明柱、胡睿、陳翔。申請號：202010705199.3
11. PCT專利名稱：CD147-ANTIBODIES AND ANTI-CD147-CAR-T CELLS。發明人：陳翔、印明柱。申請號：119995-8033.US00
12. 專利名稱：一種人細胞外基質金屬蛋白酶誘導因子磁微粒化學發光免疫定量檢測試劑盒及其檢測方法。發明人：印明柱、陳翔。申請號：202210207499.8
13. 專利名稱：5-硫-D-葡萄糖的合成方法。發明人：廖瀟嘯、印明柱、陳翔。申請號：202210336519.1
14. 專利名稱：一種同時識別多種惡性腫瘤細胞的核酸適體及其套用。發明人：蒲穎、印明柱、陳翔。專利號：ZL 2022 1 0207946.X 授權號：CN 114507668 B

發表文章

（共發表SCI論文94篇，第一/通訊（含共同）44篇,Google學術H指數32）
2023年
  1. Huang L, Wang X, Pei S, Li X, Dong L, Bian X, Sun H, Jin L, Hou H, Shi W, Zhang X, Zhang L, Zhao S, Chen X, Yin M*. Single-cell profiling reveals sustained immune infiltration, surveillance, and tumor heterogeneity in infiltrative BCC. J Invest Dermatol. 2023, S0022-202X(23)02066-3. doi: 10.1016/j.jid.2023.04.020.
  2. Liu T, Fang ZY, Li X, Zhang LN, Cao DS*, Yin MZ*. Graph deep learning enabled spatial domains identification for spatial transcriptomics. Brief Bioinform. 2023 May 19, 24(3):bbad146. doi: 10.1093/bib/bbad146.
  3. Guo Y, Jin L, Dong L, Zhang M, Kuang Y, Chen X*, Zhu W*, Yin M*. NHWD-1062 ameliorates inflammation and proliferation by the RIPK1/NF-κB/TLR1 axis in Psoriatic Keratinocytes. BIOMED PHARMACOTHER. 2023 Jun, 162: 114638. doi: 10.1016/j.biopha.2023.114638.
  4. Hu R, Li Y, Guo Y, Li X, Du S, Liao M, Hou H, Sun H, Zhao S, Su J, Chen X*, Yin M*. BRD4 inhibitor suppresses melanoma metastasis via the SPINK6/EGFR-EphA2 pathway. Pharmacol Res. 2023 Jan, 187: 106609. doi: 10.1016/j.phrs.2022.106609.
  5. Zeng F, Li Y, Meng Y, Sun H, He Y, Yin M*, Chen X*, Deng G*. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Exp Mol Med. 2023 Feb, 55(2): 364-376. doi: 10.1038/s12276-023-00936-y.
  6. Li Z, Wu X, Chen S, Zhong J, Qiu X, Kpegah JKSK, Shi K, Can L, Zhang X, Yin M, Xie H, Su J, Zhou J. Identification of CRKL as an oncogenic biomarker for prognosis and immunotherapy in melanoma, and its potential molecular mechanism. Genomics. 2023, 115 (3): 110634. doi: 10.1016/j.ygeno.2023.110634.
  7. Hongyin Sun, Kui Deng, Xingchen Zhou, Dongsheng Cao, Yan Cheng, Xiang Chen, Mingzhu Yin*. A novel gene prognostic signature lymphocyte cytosolic protein 2 regulates melanoma progression by activating tumor-infiltrating CD8+ T-cells through the interferon regulatory factor 5 signaling pathway. Tumor Discovery 2023, 2(1), 318. https://doi.org/10.36922/td.318.2022年
  8. Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M*, Yan Q*. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. SCI TRANSL MED. 2022 Feb 2, 14 (630): eabf5473. doi: 10.1126/scitranslmed.abf5473.
  9. Du S, Zeng F, Sun H, Liu Y, Han P, Zhang B, Xue W, Deng G*, Yin M*, Cui B*. Prognostic and therapeutic significance of a novel ferroptosis related signature in colorectal cancer patients. BIOENGINEERED. 2022 Feb, 13 (2): 2498-2512. doi: 10.1080/21655979.2021.2017627.
  10. Deng G, Zeng F, He Y, Meng Y, Sun H, Su J, Zhao S, Cheng Y, Chen X*, Yin M*. EEF2K silencing inhibits tumour progression through repressing SPP1 and synergizes with BET inhibitors in melanoma. Clinical and Translational Medicine. 2022 Feb, 12(2): e722. doi: 10.1002/ctm2.722.
  11. Sun H, Huang B*, Cao J*, Yan Q*, Yin M*. Editorial: Epigenetic Regulation and Tumor Immunotherapy. Front Oncol. 2022 May 5, 12: 893157. doi: 10.3389/fonc.2022.893157.
  12. Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, He J, Wen Y, Liao M, Li X, Zhou X, Song J, Ren X, Yi W, Yang J, Chen X, Yin M*, Cheng Y*. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma. J Immunother Cancer. 2022 Mar, 10(3): e004026. doi: 10.1136/jitc-2021-004026.
  13. Peng C, Jian X, Xie Y, Li L, Ouyang J, Tang L, Zhang X, Su J, Zhao S, Liu H, Yin M, Wu D, Wan M, Xie L, Chen X. Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing. Br J Dermatol. 2022, 186(6): 997-1009. doi: 10.1111/bjd.20976.
  14. Jiang R, Xu J, Zhang Y, Liu J, Wang Y, Chen M*, Chen X*, Yin M*. Ligustrazine alleviates psoriasis-like inflammation through inhibiting TRAF6/c-JUN/NFκB signaling pathway in keratinocyte. Biomed Pharmacother. 2022 Jun, 150: 113010. doi: 10.1016/j.biopha.2022.113010.
  15. Farshidfar F, Rhrissorrakrai K, Levovitz C, Peng C, Knight J, Bacchiocchi A, Su J, Yin M, Sznol M, Ariyan S, Clune J, Olino K, Parida L, Nikolaus J, Zhang M, Zhao S, Wang Y, Huang G, Wan M, Li X, Cao J, Yan Q, Chen X, Newman AM, Halaban R. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nat Commun. 2022,13(1): 898. doi: 10.1038/s41467-022-28566-4.
  16. Fu X , Yin M*. Monocytes in tumor: from the sight of Single-cell analysis. Tumor Discovery. 2022, 1 (1): 1-19.
  17. Yin M. Editor's foreword to the inaugural issue of Tumor Discovery. Tumor Discovery. 2022, 1 (1): 1-3.
  18. Zhang X, Guo Y, Xiao T, Li J, Guo A, Lei L, Jin C, Long Q, Su J, Yin M, Liu H, Chen C, Zhou Z, Zhu S, Tao J, Hu S, Chen X, Peng C. CD147 mediates epidermal malignant transformation through the RSK2/AP-1 pathway. J Exp Clin Cancer Re, 2022, 41(1): 246. doi: 10.1186/s13046-022-02427-w.
  19. Wang W, Liu X, Zhang Z, Yin M, Chen X, Zhao S, Wu L. Apigenin Induced Apoptosis by Downregulating Sulfiredoxin Expression in Cutaneous Squamous Cell Carcinoma. OXID MED CELL LONGEV. 2022, 2022: 8172866. doi: 10.1155/2022/8172866.
  20. Xiao Y, Jing D, Tang Z, Peng C, Yin M, Liu H, Chen X, Shen M. Serum lipids and risk of incident psoriasis: a prospective cohort study from the UK Biobank study and Mendelian randomization analysis. J Invest Dermatol, 2022, 142(12): 3192-3199.e12. doi: 10.1016/j.jid.2022.06.015.
  21. Zhang Y, Xia J, Zhang J, Mao J, Chen H, Lin H, Jiang P, He X, Xu X, Yin M*, Wang Z*. Validity of a Soft and Flexible 3D-Printed Nissen Fundoplication Model in Surgical Training. International Journal of Bioprinting, 2022 Mar 23, 8 (2): 546. doi: 10.18063/ijb.v8i2.546.
  22. Li X, Zhao S, Bian X, Zhang L, Lu L, Pei S, Dong L, Shi W, Huang L, Zhang X, Chen M, Chen X*, Yin M*. Signatures of EMT, immunosuppression, and inflammation in primary and recurrent human cutaneous squamous cell carcinoma at single-cell resolution. Theranostics, 2022 Oct 31, 12(17): 7532-7549. doi: 10.7150/thno.77528.
  23. Wu S, Li X, Shang L, Wu L, Li T, Li P, Ji Z, Hou J, Yin M*, Xu W*. The novel BRDT inhibitor NHWD870 shows potential as a male contraceptive in mice. Acta Biochim Biophys Sin (Shanghai). 2022, 54(12): 1789-1800. doi: 10.3724/abbs.2022135.2021年
  24. Pei S, Yuan X, Zhang Z, Yao R, Xie Y, Shen M, Li B*, Chen X*, Yin M*. Convalescent Plasma to Treat COVID-19: Clinical Experience and Efficacy. Aging (Albany NY). 2021 Mar 18, 13 (6): 7758-7766. doi: 10.18632/aging.202795.
  25. Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X, Peng C. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 2021, 503: 240-248. doi: 10.1016/j.canlet.2020.11.018.
  26. Vouga M, Favre G, Martinez-Perez O,......, Yin M, Haessig A, Ackermann S, Baud D, Panchaud A. Maternal outcomes and risk factors for COVID-19 severity among pregnant women. Sci Rep. 2021;11(1):13898. doi: 10.1038/s41598-021-92357-y.
  27. Lu Y, Xiao Y, Yin MZ, Zhou XC, Wu LS, Chen WQ, Luo Y, Kuang YH, Zhu W. Polyethylene Glycol Ointment Alleviates Psoriasis-Like Inflammation Through Down-Regulating the Function of Th17 Cells and MDSCs. Front Med (Lausanne). 2021, 7: 560579. doi: 10.3389/fmed.2020.560579.
  28. Dong L, Pei S, Ren Q, Fu S, Yu L, Chen H, Chen X*, Yin M*. Evaluation of vertical transmission of SARS-CoV-2 in utero: Nine pregnant women and their newborns. Placenta. 2021, 111: 91-96. doi: 10.1016/j.placenta.2021.06.007.
  29. Fu L, Yang ZY, Yang ZJ, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS. QSAR-assisted-MMPA to expand chemical transformation space for lead optimization. Brief Bioinform. 2021, 22(5): bbaa374. doi: 10.1093/bib/bbaa374.
  30. Yang ZY, Dong J, Yang ZJ, Yin M, Jiang HL, Lu AP, Chen X, Hou TJ, Cao DS. ChemFLuo: a web-server for structure analysis and identification of fluorescent compounds. Brief Bioinform. 2021, 22(4): bbaa282. doi: 10.1093/bib/bbaa282.
  31. Guo Y, Shen M, Zhang X, Xiao Y, Zhao S, Yin M, Bu W, Wang Y, Chen X, Su J. Unemployment and Health-Related Quality of Life in Melanoma Patients During the COVID-19 Pandemic. Front Public Health. 2021, 9: 630620. doi: 10.3389/fpubh.2021.630620.
  32. Yang ZY, Yang ZJ, Zhao Y, Yin MZ, Lu AP, Chen X, Liu S, Hou TJ, Cao DS. PySmash: Python package and individual executable program for representative substructure generation and application. Brief Bioinform. 2021, 22(5): bbab017. doi: 10.1093/bib/bbab017.
  33. Hu R, Zhao S, Su J, Chen X*, Yin M*. Establishment of cultured primary acral melanoma cells and animal models for Chinese patients. Pigment Cell Melanoma Res. 2021 Nov, 34 (6): 1131-1137. doi: 10.1111/pcmr.12996.
  34. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021, 49(W1): W5-W14. doi: 10.1093/nar/gkab255.
  35. Jiang Y, Wang G, Mu H, Ma X, Wang Z, Lv Y, Zhang T, Xu J, Wang J, Li Y, Han J, Yang M, Wang Z, Zeng K, Jin X, Xue S, Yin M, Sun W, Hua Y, Cai Z. Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling. Front Oncol. 2021, 11: 642134. doi: 10.3389/fonc.2021.642134.
  36. Liu N, Zhang J, Yin M, Liu H, Zhang X, Li J, Yan B, Guo Y, Zhou J, Tao J, Hu S, Chen X, Peng C. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Mol Ther. 2021, 29(7): 2321-2334. doi: 10.1016/j.ymthe.2021.03.013.
  37. Zhang SM, Cai WL, Liu X, Thakral D, Luo J, Chan LH, McGeary MK, Song E, Blenman KRM, Micevic G, Jessel S, Zhang Y, Yin M, Booth CJ, Jilaveanu LB, Damsky W, Sznol M, Kluger HM, Iwasaki A, Bosenberg MW, Yan Q. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. NATURE. 2021, 598 (7882): 682-687. doi: 10.1038/s41586-021-03994-2.2020年
  38. Hu R, Han C, Pei S, Yin M*, Chen X*. Procalcitonin Levels in COVID-19 Patients. Int J Antimicrob Agents. 2020 Aug, 56(2):106051. doi: 10.1016/j.ijantimicag.2020.106051.
  39. Jin L, Liu P, Yin M, Zhang M, Kuang Y, Zhu W. RIPK1: A rising star in inflammatory and neoplastic skin diseases. J Dermatol Sci. 2020, 99(3): 146-151. doi: 10.1016/j.jdermsci.2020.06.001.
  40. Yin M*, Guo Y, Hu R, Cai WL, Li Y, Pei S, Sun H, Peng C, Li J, Ye R, Yang Q, Wang N, Tao Y, Chen X, Yan Q. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun. 2020 Apr 14, 11(1): 1833. doi: 10.1038/s41467-020-15290-0.
  41. Liu N, Qi M, Li K, Zeng W, Li J, Yin M, Liu H, Chen X, Zhang J, Peng C. CD147 Regulates Melanoma Metastasis via the NFAT1-MMP-9 Pathway. Pigment Cell Melanoma Res. 2020, 33(5): 731-743. doi: 10.1111/pcmr.12886.
  42. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020, 96: 467-474. doi: 10.1016/j.ijid.2020.05.055.
  43. Deng G, Zeng F*, Zhang L*, Chen H*, Chen X*, Yin M*. Characteristics of Pregnant COVID-19 Patients with Liver Injury. J Hepatol. 2020 Oct, 73(4): 989-991. doi: 10.1016/j.jhep.2020.06.022.
  44. Li Z, Yin M, Zhang H, Ni W, Pierce RW, Zhou HJ, Min W. BMX Represses Thrombin-PAR1-Mediated Endothelial Permeability and Vascular Leakage During Early Sepsis. Circ Res. 2020 Feb 14, 126(4): 471-485. doi: 10.1161/CIRCRESAHA.119.315769.
  45. Xue Y, Liu Y, Bian X, Zhang Y, Li Y*, Zhang Q*, Yin M*. miR-205-5p Inhibits Psoriasis-Associated Proliferation and Angiogenesis: Wnt/β-catenin and Mitogen-Activated Protein Kinase Signaling Pathway Are Involved. J Dermatol. 2020, 47(8): 882-892. doi: 10.1111/1346-8138.15370.
  46. Chen XS, Wang KS, Guo W, Li LY, Yu P, Sun XY, Wang HY, Guan YD, Tao YG, Ding BN, Yin M, Ren XC, Zhang Y, Chen CS, Ye YC, Yang JM, Cheng Y. UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer. Theranostics. 2020, 10(4): 1833-1848. doi: 10.7150/thno.39814.
  47. Pei S, Xue Y, Zhao S, Alexander N, Mohamad G, Chen X*, Yin M*. Occupational Skin Conditions on the Front Line: A Survey Among 484 Chinese Healthcare Professionals Caring for Covid-19 Patients. J Eur Acad Dermatol Venereol. 2020 Aug, 34(8): e354-e357. doi: 10.1111/jdv.16570.
  48. Li LY, Chen XS, Wang KS, Guan YD, Ren XC, Cao DS, Sun XY, Li AX, Tao YG, Zhang Y, Yin MZ, Wang XL, Wu MH, Yang JM, Cheng Y. RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy. Oncogene. 2020, 39(43): 6704-6718. doi: 10.1038/s41388-020-01447-0.
  49. Liao M, Zeng F, Li Y, Gao Q, Yin M, Deng G, Chen X. A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients. Sci Rep. 2020, 10(1): 12462. doi: 10.1038/s41598-020-69330-2.
  50. Guo Y, Shen M, Zhang X, Xiao Y, Zhao S, Yin M, Bu W, Wang Y, Chen X, Su J. Association of Socioeconomic Changes due to the COVID-19 Pandemic With Health Outcomes in Patients With Skin Diseases: Cross-Sectional Survey Study. J Med Internet Res. 2020, 22(9): e22288. doi: 10.2196/22288.
  51. Deng G, Zeng F, Su J, Zhao S, Hu R, Zhu W, Hu S, Chen X*, Yin M*. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway. Theranostics. 2020 Sep 15, 10(25): 11428-11443. doi: 10.7150/thno.47432.
  52. Guan Y, Jiang S, Ye W, Ren X, Wang X, Zhang Y, Yin M, Wang K, Tao Y, Yang J, Cao D, Cheng Y. Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy. Cell Death Dis. 2020, 11(11): 948. doi: 10.1038/s41419-020-03153-x.
  53. Yang SQ, Ye Q, Ding JJ, Yin MZ, Lu AP, Chen X, Hou TJ, Cao DS. Current advances in ligand-based target prediction. WIREs Comput Mol Sci. 2020, 1-21. doi: 10.1002/wcms.1504.
  54. Jin L, Liu P, Yin M, Zhang M, Kuang Y, Zhu W. RIPK1: A rising star in inflammatory and neoplastic skin diseases. J Dermatol Sci. 2020, 99(3): 146-151. doi: 10.1016/j.jdermsci.2020.06.001.
  55. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Crit Care. 2020, 24(1): 179. doi: 10.1186/s13054-020-02902-w.
  56. Liu P, Huang Z, Yin M, Liu C, Chen X, Pan P, Kuang Y. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial. Trials. 2020, 21(1): 999. doi: 10.1186/s13063-020-04925-8.
  57. Panchaud A, Favre G, Pomar L, Vouga M, Aebi-Popp K, Baud D; COVI-Preg group (Mingzhu Yin). An international registry for emergent pathogens and pregnancy. Lancet. 2020, 395(10235): 1483-1484. doi: 10.1016/S0140-6736(20)30981-8.
  58. Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, Ma F, Gao Q, Chang R, Lee HH, Zhao S, Su J, Li H, Peng J, Chen H, Yin M, Peng C, Yang N, Wang J, Liu J, Liu H, Han L, Chen X. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome Med. 2020, 12(1): 83. doi: 10.1186/s13073-020-00780-z.2019年
  59. Hu B, Hu H, Yin M*, Sun Z, Chen X, Li Y, Sun Z, Liu C, Li L, Qiu Y*. Sertad1 promotes prostate cancer progression through binding androgen receptor ligand binding domain. Int J Cancer. 2019,144(3): 558-568. doi: 10.1002/ijc.31877.
  60. Yin M, Zhou HJ, Lin C, Long L, Yang X, Zhang H, Taylor H, Min W*. CD34+ KLF4+ Stromal Stem Cells Contribute to Endometrial Regeneration and Repair. Cell Rep. 2019, 27(9): 2709-2724.e3. doi: 10.1016/j.celrep.2019.04.088.2018年
  61. Li J, Yin M, Song W, Cui F, Wang W, Wang S, Zhu H. B Subunit of Human Chorionic Gonadotropin Promotes Tumor Invasion and Predicts Poor Prognosis of Early-Stage Colorectal Cancer. Cell Physiol Biochem. 2018, 45(1): 237-249. doi: 10.1159/000486770.
  62. Long L, Yin M, Min W. 3D Co-culture System of Tumor-associated Macrophages and Ovarian Cancer Cells. Bio Protoc. 2018 Apr 20, 8(8): e2815. doi: 10.21769/BioProtoc.2815.
  63. Han Z, Hu H, Yin M, Li X, Li J, Liu L, Liu B. miR-145 is critical for modulation of vascular smooth muscle cell proliferation in human carotid artery stenosis. J BIOL REG HOMEOS AG. 2018 May-Jun, 32 (3): 506-516.2017年
  64. Li L, Wei X, Wu B, Xiao Y, Yin M*, Yang Q*. siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells. ONCOL LETT. 2017, 13 (5): 3014-3024. doi: 10.3892/ol.2017.5828.
  65. Zhang L, Fu Z, Li X, Tang H, Luo J, Zhang D, Zhuang Y, Han Z*, Yin M*. Transforming growth factor β-activated kinase 1 inhibitor suppresses the proliferation in triple-negative breast cancer through TGF-β/TGFR pathway. CHEM BIOL DRUG DES. 2017, 90 (3): 450-455. doi: 10.1111/cbdd.12965.
  66. Yang K, Xia B, Wang W, Cheng J, Yin M, Xie, H, Li, J, Ma, L, Yang, C, Li, A, Fan, X, Dhillon, HS, Hou, Y, Lou, G, Li, K. A Comprehensive Analysis of Metabolomics and Transcriptomics in Cervical Cancer. Sci Rep. 2017, 7: 43353. doi: 10.1038/srep43353.
  67. Tan S, Feng B, Yin M, Zhou HJ, Lou G, Ji W, Li Y, Min W. Stromal Senp1 promotes mouse early folliculogenesis by regulating BMP4 expression. Cell Biosci. 2017, 7: 36. doi: 10.1186/s13578-017-0163-5.
  68. Yin M, Zhou HJ, Zhang J, Lin C, Li H, Li X, Li Y, Zhang H, Breckenridge DG, Ji W, Min W. ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis. JCI Insight. 2017, 2 (18): e91828. doi: 10.1172/jci.insight.91828.2016年
  69. Yin MZ, Tan S, Li X, Hou Y, Cao G, Li K, Kou J, Lou G. Identification of phosphatidylcholine and lysophosphatidylcholine as novel biomarkers for cervical cancers in a prospective cohort study. TUMOR BIOL. 2016, 37 (4): 5485-5492. doi: 10.1007/s13277-015-4164-x.
  70. Cui CY, Sima J, Yin M, Michel M, Kunisada M, Schlessinger D. Identification of potassium and chloride channels in eccrine sweat glands. J Dermatol Sci. 2016, 81(2): 129-131. doi: 10.1016/j.jdermsci.2015.11.001.
  71. Cao G, Ye X, Xu Y, Yin M, Chen H, Kou J, Yu B. YiQiFuMai powder injection ameliorates blood-brain barrier dysfunction and brain edema after focal cerebral ischemia-reperfusion injury in mice. Drug Des Devel Ther. 2016, 10: 315-325. doi: 10.2147/DDDT.S96818.
  72. Huang B, Yin M, Li X, Cao G, Qi J, Lou G, Sheng S, Kou J, Chen K, Yu B. Migration-inducing gene 7 promotes tumorigenesis and angiogenesis and independently predicts poor prognosis of epithelial ovarian cancer. Oncotarget. 2016, 7(19): 27552-27566. doi: 10.18632/oncotarget.8487.
  73. Fan L, Yin M, Ke C, Ge T, Zhang G, Zhang W, Zhou X, Lou G, Li K. Use of Plasma Metabolomics to Identify Diagnostic Biomarkers for Early Stage Epithelial Ovarian Cancer. J Cancer. 2016, 7 (10): 1265-1272. doi: 10.7150/jca.15074.
  74. Zou S, Teixeira AM, Yin M, Xiang Y, Xavier-Ferrucio J, Zhang PX, Hwa J, Min W, Krause DS. Leukaemia-associated Rho guanine nucleotide exchange factor (LARG) plays an agonist specific role in platelet function through RhoA activation. Thromb Haemost. 2016,116(3): 506-516. doi: 10.1160/TH15-11-0848.
  75. Cao G, Jiang N, Hu Y, Zhang Y, Wang G, Yin M, Ma X, Zhou K, Qi J, Yu B, Kou J. Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway. Int J Mol Sci. 2016, 17(9): 1418. doi: 10.3390/ijms17091418.
  76. Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016, 126(11): 4157-4173. doi: 10.1172/JCI87252.2015年
  77. Ye Y, Yin M, Huang B, Wang Y, Li X, Lou G. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer. Tumour Biol. 2015, 36(6): 4175-4179. doi: 10.1007/s13277-015-3052-8.
  78. Ji W, Li Y, He Y, Yin M, Zhou HJ, Boggon TJ, Zhang H, Min W. AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis. CANCER RES. 2015, 75 (17): 3492-3504. doi: 10.1158/0008-5472.CAN-15-0088.2014年
  79. Cui CY, Yin M, Sima J, Childress V, Michel M, Piao Y, Schlessinger D. Involvement of Wnt, Eda and Shh at defined stages of sweat gland development. Development. 2014, 141(19): 3752-60. doi: 10.1242/dev.109231.
  80. Hou Y, Yin M, Sun F, Zhang T, Zhou X, Li H, Zheng J, Chen X, Li C, Ning X, Lou G, Li K. A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients. Mol Biosyst. 2014, 10(8): 2126-33. doi: 10.1039/c4mb00054d.
  81. Ge T, Yin M, Yang M, Liu T, Lou G. MicroRNA-302b suppresses human epithelial ovarian cancer cell growth by targeting RUNX1. Cell Physiol Biochem. 2014, 34(6): 2209-2220. doi: 10.1159/000369664.2013年
  82. Zhang T, Wu X, Ke C, Yin M, Li Z, Fan L, Zhang W, Zhang H, Zhao F, Zhou X, Lou G, Li K. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res. 2013, 12(1): 505-512. doi: 10.1021/pr3009572.
  83. Yin M, Hou Y, Zhang T, Cui C, Zhou X, Sun F, Li H, Li X, Zheng J, Chen X, Li C, Ning X, Li K, Lou G. Evaluation of chemotherapy response with serum squamous cell carcinoma antigen level in cervical cancer patients: a prospective cohort study. PLoS One. 2013, 8(1): e54969. doi: 10.1371/journal.pone.0054969.2012年
  84. Yin M, Lou C, Zhang W, Meng F, Zhang H, Ning X, Zhou R, Dong X, Lou G. LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors. Int J Gynecol Cancer. 2012 Jan;22(1):54-62. doi: 10.1097/IGC.0b013e318234f9ac.
  85. Zhang T, Wu X, Yin M, Fan L, Zhang H, Zhao F, Zhang W, Ke C, Zhang G, Hou Y, Zhou X, Lou G, Li K. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta. 2012 May 18;413(9-10):861-8. doi: 10.1016/j.cca.2012.01.026.
  86. Fan L, Zhang W, Yin M, Zhang T, Wu X, Zhang H, Sun M, Li Z, Hou Y, Zhou X, Lou G, Li K. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol. 2012 Apr; 51(4): 473-9. doi: 10.3109/0284186X.2011.648338.
  87. Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y, Huang Y. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg. 2012 Nov;204(5):677-83. doi: 10.1016/j.amjsurg.2012.02.003.
  88. Yin M, Zhang H, Li H, Li X, Liu Y, Chen X, Lou G, Li K. The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. J Surg Oncol. 2012 Feb;105(2):206-11. doi: 10.1002/jso.22052.2011年
  89. Meng F, Song H, Luo C, Yin M, Xu Y, Liu H, Zhou R, Lou G. Correlation of LAPTM4B polymorphisms with cervical carcinoma. Cancer. 2011 Jun 15;117(12):2652-8. doi: 10.1002/cncr.25833.
  90. Yin M, Li C, Li X, Lou G, Miao B, Liu X, Meng F, Zhang H, Chen X, Sun M, Ling Q, Zhou R. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol. 2011 Jul 1;104(1):29-36. doi: 10.1002/jso.21912.
  91. Yin M, Zhao F, Lou G, Zhang H, Sun M, Li C, Hou Y, Li X, Meng F, Chen X. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer. Int J Gynecol Cancer. 2011 Jan;21(1):92-9. doi: 10.1111/IGC.0b013e3181fe8b6e.
  92. Yin M, Xu Y, Lou G, Hou Y, Meng F, Zhang H, Li C, Zhou R. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2011 Aug 1;129(3):629-35. doi: 10.1002/ijc.25689.2010年
  93. Meng F, Luo C, Hu Y, Yin M, Lin M, Lou G, Zhou R. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol. 2010 Nov;29(6):587-93. doi: 10.1097/PGP.0b013e3181e0898e.
  94. Meng FL, Yin MZ, Song HT, Yang H, Lou G, Zhou RL. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2010 Jul;20(5):745-50. doi: 10.1111/IGC.0b013e3181e02f90.

相關詞條

熱門詞條

聯絡我們